U.S. markets open in 9 hours 18 minutes
  • S&P Futures

    3,836.25
    +9.00 (+0.24%)
     
  • Dow Futures

    31,125.00
    +64.00 (+0.21%)
     
  • Nasdaq Futures

    11,653.75
    +42.50 (+0.37%)
     
  • Russell 2000 Futures

    1,730.40
    +1.90 (+0.11%)
     
  • Crude Oil

    110.15
    +1.72 (+1.59%)
     
  • Gold

    1,811.30
    +9.80 (+0.54%)
     
  • Silver

    20.07
    +0.47 (+2.41%)
     
  • EUR/USD

    1.0438
    +0.0014 (+0.14%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • Vix

    27.53
    -1.18 (-4.11%)
     
  • GBP/USD

    1.2111
    +0.0007 (+0.05%)
     
  • USD/JPY

    136.1720
    +0.5120 (+0.38%)
     
  • BTC-USD

    20,268.92
    +1,174.91 (+6.15%)
     
  • CMC Crypto 200

    440.00
    +19.86 (+4.73%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • Nikkei 225

    26,330.94
    +177.13 (+0.68%)
     

ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).

  • STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves).

  • After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study.

  • Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) company.

  • Also Read: Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies.

  • IMX-110 was compared against approved drugs used to treat STS in this study.

  • According to Meco et al., 2003 (trabectedin monotherapy treatment arm), trabectedin was dosed, and IMX-110 was administered at 2.0 mg/kg.

  • "We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies," said Ilya Rachman, CEO of ImmixBio. "We believe this is a preview of anti-tumor activity to be demonstrated in our two clinical trials to be kicked off in 2022: IMX-110 monotherapy and IMX-110 in combination with anti-PD-1 tislelizumab."

  • Price Action: IMMX shares are up 57.7% at $2.57 during the market session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.